MedTrace Logo

Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors

NCT01936961 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2017-06-27

No results posted yet for this study

Summary

The purpose of this study is to use Immunochemotherapy +/- Hypofractionated Radiation for complete response in solid tumors

Conditions

Interventions

DRUG

CTLA-4 Antibody

administered intravenously over 90 minutes every 3 weeks for a total of four doses

RADIATION

Hypofractionated Radiotherapy

Sponsors & Collaborators

  • Western Regional Medical Center

    lead OTHER

Principal Investigators

  • Glen J Weiss, MD · Western Regional Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01936961 on ClinicalTrials.gov